Brief: Affimed Announces Positive Early Efficacy And Progression Free Survival Results Of AFM24-102 Study In EGFR Wild-Type Non-Small Cell Lung Cancer

Affimed NV

23/05/2024 23:56

May 23 (Reuters) - Affimed NV  A28A.F :
    * AFFIMED ANNOUNCES POSITIVE EARLY EFFICACY AND PROGRESSION
FREE
SURVIVAL RESULTS OF AFM24-102 STUDY IN EGFR WILD-TYPE NON-SMALL
CELL LUNG CANCER AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY
OF CLINICAL ONCOLOGY 2024
    * AFFIMED: IN 15 RESPONSE-EVALUABLE PATIENTS WITH METASTATIC
EGFR
WILD-TYPE NSCLC, COMBO OF AFM24 & ATEZOLIZUMAB LED TO DISEASE
CONTROL RATE OF 73.3%
    * AFFIMED NV: AS OF MARCH 18, 2024 DATA CUT-OFF, MEDIAN
PROGRESSION FREE SURVIVAL WAS 5.9 MONTHS AND 3 OF 4 RESPONSES
WERE ONGOING

Source text for Eikon:  ID:nGNX2G9f92 
Further company coverage:  A28A.F 

 ((Reuters.Briefs@thomsonreuters.com;))